a Aim/Objective/Background Direct-acting oral anticoagulant drugs are marketed worldwide for the primary and secondary prevention and treatment of thromboembolic disorders. Rivaroxaban, an oral, direct factor Xa inhibitor, is one of the most used. Rivaroxaban-induced hepatotoxicity is unusual, although a number of adverse reports have recently been reported. Here, we report two new cases of rivaroxaban-induced hepatitis. Methods A systematic search of case reports on the MEDLINE database encompassing the years 2008-2016 was carried out. Additional references were obtained following a manual search of the retrieved papers. We report two new cases of adverse events occurred in patients treated with rivaroxaban (20 mg/die) to prevent systemic embolism, who presented with hepatocellular liver injury with onset at 8 weeks after initiation of the drug intake. Results Twenty-six cases were retrieved from MEDLINE (57.7% female, 42.3% male). Using the Roussel Uclaf Causality Assessment Method (RUCAM) scale, liver injury was classified as hepatocellular (42.3%), cholestatic (26.9%), or mixed (15.4%). Older age (≥65 years) was present as a risk factor in 57.7%. The time lapse between initiation of treatment and onset of hepatic injury ranged from 2 to 180 days (median: 15 days). Our two new patients were diagnosed with drug-induced liver injury (hepatocellular pattern) using the 'consensus criteria', for drug-induced liver injury. Their RUCAM scores were calculated and assessed as highly probable and probable, respectively. A clinical recovery after rivaroxaban withdrawal was observed. Conclusion Direct-acting oral anticoagulants have been commonly prescribed, even if safety issues regarding the use of these drugs are still an ongoing concern, especially in patients experiencing chronic liver disease. Dedicated postauthorization safety studies should be undertaken to better define rivaroxaban-induced drug-induced liver injury. 
Introduction
Direct-acting oral anticoagulants (DOACs) are direct thrombin and factor Xa (activated factor X) inhibitors. These drugs, unlike the standard oral vitamin K antagonists (e.g. warfarin), are active from the first dose and have predictable pharmacokinetic properties that allow fixeddose administration without regular anticoagulant activity monitoring. However, all currently available DOACs are associated with a small risk of idiosyncratic hepatotoxicity [1, 2] . The first DOAC marketed was ximelagatran, a direct thrombin inhibitor approved in many countries for primary deep vein thrombosis (DVT) prophylaxis after orthopedic surgery [1] . The tolerability of ximelagatran was initially reported as acceptable in short-term clinical trials, whereas in longer treatment durations,~8% of patients experienced elevated liver function values at least three times over the upper limit of normal, almost all of these cases occurring within the first 6 months of therapy [3] . Consequently, given the possible risk of hepatotoxicity, the drug was withdrawn from the market in 2006 [4] . The more recently developed DOACs have been thoroughly investigated in preclinical and clinical trials for the possibility of hepatic and other toxicities [2] .
At present, the DOACs approved for use in the EU, as well as in other countries, are the direct thrombin inhibitor dabigatran [5] and the direct factor Xa inhibitors, rivaroxaban [6] , apixaban [7] , and edoxaban [8] . Rivaroxaban is the first oral direct factor Xa inhibitor to have been marketed worldwide since 2008. It has been approved for the treatment of DVT, the prevention of recurrent DVT and pulmonary embolism, the prevention of strokes and systemic embolism in adults with atrial fibrillation and in adults undergoing hip/knee replacement surgery, and the prevention of atherothrombotic events after acute coronary syndrome [6] .
With the exception of dabigatran, all DOACs are metabolized in the liver, and therefore, associated with liver function alteration. Rivaroxaban is metabolized by cytochrome P450 (CYP) 3A4, CYP2J2, and CYPindependent mechanisms, and, further, is a substrate of P-glycoprotein (P-gp) [1, 9] . According to the EU summary of product characteristics [6] , the concomitant use of rivaroxaban and strong inhibitors of both CYP3A4 and P-gp (such as ketoconazole and itraconazole) is not recommended. These active substances may increase rivaroxaban plasma concentrations to a clinically hazardous degree, which may lead to an increased bleeding risk [6, 9] . Drugs that inhibit only one of these pathways, such as clarithromycin and erythromycin, are less potent inhibitors and do not appear to have clinically relevant effects. Potent inducers of CYP3A4, such as rifampicin, may reduce the effect of rivaroxaban.
Although rivaroxaban-induced hepatoxicity is unusual, liver injury events had already been reported in premarketing trials [10] . More recently, a number of case series of patients treated with rivaroxaban and diagnosed as having druginduced liver injury (DILI) have been published [2, 10, 11] . DILI induced by rivaroxaban is idiosyncratic and covers a broad spectrum of manifestations, ranging from asymptomatic liver enzyme elevation to severe hepatic failure requiring liver transplantation [12] . In this context, we report two more cases of rivaroxaban-induced hepatotoxicity and, further, we reviewed the currently available literature on this topic.
Patients and methods
To review the literature regarding rivaroxaban-induced hepatotoxicity, we carried out a systematic search for all pertinent reports on the MEDLINE database encompassing the years from 2008 to 2016. Keywords used for liver damage were as follows: hepatotoxicity, liver injury, hepatitis, cholestasis, liver failure, liver necrosis, liver fibrosis, and cirrhosis. Each term was cross-matched with rivaroxaban. There were no restrictions regarding article type, patient sex or age, and language of publication. Additional information was also extracted from the references of all the retrieved papers.
Currently, we are carrying out a prospective study, collecting all cases of DILI observed at our Department of Internal Medicine and Specialties, since January 2000. Among these, we found two cases showing hepatocellular liver injury attributable to rivaroxaban exposure. The causality assessment on these cases was assessed using the Roussel Uclaf Causality Assessment Method (RUCAM) [13] . The Naranjo algorithm for causality assessment [14] was also applied to our cases, although it is not liver specific and possibly lacking in specificity and reproducibility for evaluating drug-associated hepatotoxicity [15] .
Results
Twenty-six cases of acute or subacute liver damage following rivaroxaban exposure were retrieved from MEDLINE search between the years 2008 and 2016 (Table 1) [11, [16] [17] [18] [19] [20] [21] [22] . Fifteen (57.7%) patients were female and 11 (42.3%) male. This corresponds to a female/male ratio of 1 : 36, with an age ranging from 25 to 91 years at the time of diagnosis (median: 68 years). Age (≥65 years) was a risk factor present in 15 (57.7%) patients. The time between initiation of rivaroxaban intake and onset of liver injury ranged from 2 to 180 days (median: 15 days). The indications for therapy were typically prevention from venous thromboembolism in patients undergoing elective hip or knee replacement surgery and prevention from stroke and systemic embolism in patients with nonvalvular atrial fibrillation. Using the RUCAM scale, liver injury was classified as hepatocellular (42.3%), cholestatic (26.9%), or mixed (15.4%). Histological examination, when performed, showed inflammatory reactions, necrosis, and cholestasis (Table 1) [11, 16, 19] .
Serum analysis confirmed a negative viral serology for active hepatitis B and C in all patients. An autoimmune reaction was excluded by measuring serum levels of nonorgan-specific autoantibodies. Alcohol abuse was also excluded. In some cases, consumption of other medications was reported. Recovery was generally observed, with the exception of two patients. One of 11 cases with predominantly hepatocellular injury (n = 11) resulted in death [18] from acute liver failure. Among the cholestatic cases (n = 7), one died of paralytic ileus [11] . None of the four mixed cases died [11, 16] .
In the following section, we describe the two new cases observed at our unit over the past year. Using the 'consensus criteria' for DILI these patients were diagnosed with hepatocellular liver injury. The RUCAM scores were calculated as 9 (highly probable) and 8 (probable), respectively. Therefore, rivaroxaban intake was interrupted, whereas any other medications were continued. A rapid normalization of aminotransferase values and clinical and biochemical recovery after rivaroxaban withdrawal were observed.
Report of new cases

Case 1
A 79-year-old White man with nonvalvular atrial fibrillation was treated with rivaroxaban (20 mg/die) to prevent systemic embolism. Two months after starting rivaroxaban treatment, he developed fatigue, jaundice, and itching and was admitted to our unit of internal medicine. The patient's features are reported in Table 2 . On admission, diagnostic tests revealed elevated serum liver enzyme levels compatible with liver hepatocellular injury: aspartate aminotransferase (AST) was 33 times above the upper normal limit (UNL); alanine aminotransferase (ALT) was 35 × UNL; total bilirubin was 21.83 mg/dl; alkaline phosphatase (AP) was 2 × UNL; and γ-glutamyl transpeptidase (GGT) was 7 × UNL. The patient had no history of alcohol or drug abuse or metabolic disease, such as diabetes. Viral hepatitis was excluded by serological laboratory tests (IgM anti-HAV, HBsAg, and IgG anti-HCV); non-organ-specific autoantibodies, antinuclear antibody, anti-mitochondrial antibody, liver-kidney microsomal antibody, were also negative. Abdominal ultrasound and contrast-enhanced computed tomography scan did not show liver steatosis, biliary obstruction, or pancreatic or liver mass; wholebody PET scan result was negative. Rivaroxaban was discontinued on the first day of hospitalization and lowmolecular-weight heparin was started; other drugs such as ramipril, bisoprolol, digoxin, and furosemide were continued because the patient had been following this therapy for a long time. The RUCAM score was calculated as 9 (rivaroxaban-induced DILI highly probable).
Relevant criteria for this case assessment were a close and plausible temporal relationship, a known and labeled adverse drug reaction, and negative differential diagnosis for any alternative diagnosis. One week after withdrawal of rivaroxaban treatment, aminotransferases level started to fall, as did bilirubin; AP was 1.5 × UNL and GGT was 7 × UNL. At follow-up, 4 weeks after the suspension of rivaroxaban treatment, serum liver enzymes were within the normal range and the patient was completely asymptomatic ( Fig. 1 ). Other drugs were therefore classified as unlikely alternative causes. The Naranjo probability scale for causality assessment [14] score was 7 (probable). The score was derived as follows: one point for the previous reports of an adverse reaction in patients treated with rivaroxaban; two points for the adverse event occurring after drug intake; one point for improvement in the adverse reaction when rivaroxaban administration was stopped, one point for the absence of alternative causes, and two points for confirmation of diagnosis by objective evidence.
Case 2
The second patient was an 84-year-old White woman, having nonvalvular atrial fibrillation, treated with rivaroxaban (20 mg/die) to prevent systemic embolism. Seven weeks after starting rivaroxaban treatment, she developed fatigue and discomfort and required hospitalization. On admission, blood tests revealed hepatocellular liver injury: AST/ALT were 3/9 UNL, GGT was 6 × UNL, and AP was within the normal range. Major hepatotropic virus serology (hepatitis A virus, hepatitis B virus, and hepatitis C virus) and nonorgan-specific autoantibodies (antinuclear antibody, antimitochondrial antibody, liver-kidney microsomal antibody) showed negative results. The patient had no history of alcohol or drug abuse or metabolic disease, such as diabetes. Abdominal liver ultrasonography and computed tomography scan showed normal findings with no signs of steatosis, biliary obstruction, or mass. Rivaroxaban intake was suspected as a potential cause for hepatocellular injury. Further clues supporting this clinical suspicion were the previous case report (case 1) and the temporal relationship (within 7 weeks). Rivaroxaban therapy was discontinued on the sixth day of hospitalization, and low-molecular-weight heparin was started, whereas any other drugs (lansoprazole, amlodipine, carvedilol, or furosemide) were continued. The RUCAM causality score was calculated as 8 (rivaroxabaninduced DILI, probable), whereas according to the Naranjo algorithm, the score was 4 (relationship 'possible'). Liver enzyme levels and GGT rapidly normalized after suspension of rivaroxaban treatment: after one week, aminotransferases were 1.5 × UNL, GGT was 2.5 UNL, and bilirubin within normal range. The patient was not further exposed to rivaroxaban (patient details are reported in Table 2 ).
Discussion
In the last 10 years, DOACs have been approved for the primary and secondary prevention and treatment of thromboembolic disorders. With the exception of dabigatran, DOACs are metabolized by the liver with the involvement of CYP3A4, and associated with liver function alteration and serum enzyme elevation at an incidence of between 1/100 and 1/1000 patients [6] [7] [8] . DOACs have been under close surveillance since ximelagatran was first associated with hepatoxicity during the postmarketing phase, leading to its withdrawal [4] . In fact, the 2013 European guidance for the use of DOACs recommends yearly monitoring of liver function [23] .
A meta-analysis of 29 phase III clinical trials, including 152 116 patients randomized to receive dabigatran, rivaroxaban, apixaban, or edoxaban versus conventional therapy or placebo, found no increased risk of hepatotoxicity with these drugs [24] . However, according to 'the rule of three' (which states that if a particular event does not occur in a population of 3000 patients, it can be concluded, with 95% confidence, that 1/1000 patients will be affected), the size of clinical trial patient populations is often too small to determine the risk levels associated with rare idiosyncratic adverse drug reactions, like DILI. In addition, clinical trial evaluations are also limited by their short treatment duration and exclusion of patients with other potential risk factors (e.g. pre-existing liver disease) [2] .
Severe and even fatal cases of acute liver toxicity in patients treated with rivaroxaban have been reported in the literature [2, 11, [16] [17] [18] [19] [20] [21] [22] . To date, rivaroxaban-induced liver injury events have been described in several case reports: in this study, we reviewed 26 published clinical reports and have added two new cases in which hepatotoxicity, assessed by RUCAM as 'probable' or 'highly probable', was the main adverse event. Furthermore, in the case series reviewed, the main features of the liver damage were the short latency and rapid onset of injury. Severe hepatotoxicity generally occurred within 15 days after initiation of rivaroxaban, most cases occurring within 7 days. The reported hepatotoxic reactions showed a clear temporal relationship between drug intake and the onset of disease: up to 95% of the patients described in the reports had been taking the drug for a period between 1 day and 2 months, and this time should be considered 'suggestive' in the causality assessment according to RUCAM. Dechallenge was always positive apart from in two patients. In particular, the time-to-onset data from the published case reports suggest that early evaluation of hepatic enzymes (i.e., within the first month) should be considered, at least in patients on a complex treatment regimen with comorbidities; subsequently, liver function can be monitored on a yearly basis [25] .
The occurrence of hepatotoxicity and the majority of fatal reports were significantly higher in patients older than 65 years. Fifteen (57.7%) of the 26 cases reviewed presented age as a possible risk factor, and both of our cases were older than 65 years. Both hepatocellular and cholestatic patterns of liver injury have been reported with rivaroxaban. In the cases reviewed, the liver injury pattern was predominantly hepatocellular (42.3%); cholestatic and mixed categories were also well distributed (26.9 and 15.4%). Hepatocellular was the pattern in our two cases. Recovery was generally observed, apart from in two patients. One of 11 cases with predominantly hepatocellular injury resulted in death from acute liver failure. Among the cholestatic cases, one resulted in death but from paralytic ileus. None of the four mixed cases resulted in death. Both of our patients had a self-limited, benign course with rapid recovery after rivaroxaban was withdrawn.
The potential mechanisms of DOAC-associated hepatotoxicity are yet to be fully determined. Among the reported cases of hepatotoxicity associated with rivaroxaban (Table 1) , findings available from four liver specimens were also compatible with both immune and nonimmune (or metabolic) mechanisms [11, 16, 19] . In two biopsies, the main findings were centroacinar cholestasis with bile duct injury and portal lymphocyte and eosinophil infiltrate, consistent with an allergic reaction [11] . The third biopsy showed focal hepatocyte necrosis and mild portal infiltrates with sporadic eosinophils; this patient was diagnosed with DRESS (drug rash with eosinophilia and systemic symptoms) syndrome, which is an human leukocyte antigen-associated cellular hypersensitivity reaction [19] . In the last biopsy, the main feature was the centroacinar necrosis, which may be caused by the accumulation of toxic metabolites and is consistent with a metabolic reaction [16] . The centroacinar/perivenular location of the hepatic necrosis observed in the specimens, corresponding to a higher density of CYP3A4, is consistent with metabolic toxicity owing to rivaroxaban and/or its metabolite rather than an immune-mediated mechanism [2, 16] . Previous studies have indicated that rivaroxaban is a shared substrate of the drug transport proteins MDR1 and BCRP; MDR1 inhibitors and loss-of-function BCRP polymorphisms may therefore alter rivaroxaban pharmacokinetics, and further studies should explore the potential role of these factors in rivaroxaban-induced DILI [23, [26] [27] [28] .
An interesting case report described a patient with suspected rivaroxaban-associated DILI that rapidly resolved after discontinuation; apixaban was then safely prescribed as an alternative factor Xa inhibitor. This implies that cross reactivity may not be present and that the mechanism of injury is likely unrelated to its mechanism of action as an anticoagulant [22] . By using, the consensus criteria for DILI [12, 13] , both our patients were diagnosed with hepatocellular liver injury, and the RUCAM score was calculated as 9 (highly probable) for the first patient and 8 (probable) for the second. Other diseases such as viral and autoimmune hepatitis, exposure to alcohol or toxins, and diabetes were excluded. The clinical pattern of liver injury was similar in the two patients, as was the clinical and biochemical response after discontinuation of rivaroxaban treatment.
Recently, analyses of large international pharmacovigilance databases showed that DOACs are likely associated with a rare but clinically relevant risk of hepatotoxicity. Consequently, by the end of 2013, the US Food and Drug Agency adverse event reporting system database contained 17 097 reports linked to DOACs. After 2 years of postmarketing surveillance, 146 reports of DILI had been submitted for rivaroxaban, compared with 222 for dabigatran and only one for apixaban. Thus, there was a definite disproportionality signal for rivaroxaban [29] . In February 2016, the European pharmacovigilance database, EudraVigilance, had accumulated 793 cases of hepatotoxicity with rivaroxaban, of which 24 cases were acute hepatitis and four fulminant hepatitis [20] . Analyzing the data, the reported cases with rivaroxaban appear to be higher, probably because it is the DOAC most prescribed in Europe, thus accounting for a larger number of exposed patients [30] . Regarding the risk of hepatotoxicity, when DOACs and warfarin are compared, the latter shows lower liver injury hospitalization rates during a follow-up of 12 months. However, among DOACs, rivaroxaban shows the highest risk [0.88, 95% confidence interval (CI): 0.75-1.03] compared with dabigatran (0.57, 95% CI: 0.46-0.71) and apixaban (0.70, 95% CI: 0.50-0.97). Predictors of liver injury hospitalization are the type of anticoagulant given, previous liver and kidney disease, cancer, anemia, heart failure, and alcohol abuse [31] .
In clinical practice, DILI represents a difficult diagnostic dilemma, being characterized by a wide range of manifestations, which vary from an asymptomatic mild increase in liver enzyme values to acute liver failure, leading to transplantation or death. Diagnosis involves excluding other potential causes of hepatotoxicity, as well as identifying a particular pattern of disease manifestation, with a temporal relationship between treatment initiation and discontinuation of the suspected drug [32] . In addition, lipophilicity and hepatic metabolism are features intrinsic to rivaroxaban, which incriminate this drug as being potentially responsible for DILI. Thus, although the actual pathophysiology is at present unknown, an idiosyncratic mechanism has been hypothesized as the consequence of rivaroxaban-induced liver injury, which usually occurs when the drug is administered at therapeutic doses and is independent from the drug's expected pharmacological properties [2] . In fact, in all the cases reviewed rivaroxaban was given at therapeutic doses. In addition, in some of the reports, older-aged patients were taking other medications that might have contributed to the liver injury [11, [16] [17] [18] 20] .
Conclusion
Rivaroxaban-induced hepatotoxicity is unusual. A potential signal for severe rivaroxaban-induced liver injury has not yet been fully characterized, although with the increasing use of this drug, clinicians should be aware of the potential risk of DILI. In fact, the intrinsic features of rivaroxaban suggest that its routine use in patients with severe liver disease is to be avoided. Moreover, all suspected cases of rivaroxaban-associated hepatotoxicity should be reported to national pharmacovigilance services to improve our understanding of this potentially lifethreatening adverse drug reaction. A complete and thorough assessment, fully analyzing the pertinent data of postauthorization safety studies, should be undertaken, and an active postmarketing surveillance of this DOAC should be continued.
